PieranDx buys Tute Genomics

PierianDx, a St. Louis-based developer of clinical genomic analysis, interpretation and reporting, has announced its acquisition of Tute Genomics, a genomics software company based in Provo.

PierianDx, a St. Louis-based developer of clinical genomic analysis, interpretation and reporting, has announced its acquisition of Tute Genomics, a genomics software company based in Provo.

The acquisition furthers PierianDx’s goal to be the most comprehensive, integrated platform to enable personalized medicine for clinical labs, according to a release from the company.

“We are excited to welcome Tute Genomics customers and employees to the PierianDx team,” said PierianDx CEO Ted Briscoe. “The enhanced platform will provide labs with a single clinical solution to support a comprehensive range of molecular testing for personalized medicine.”

As part of the transaction, Reid Robison, CEO of Tute, will join the PierianDx board of directors and Tute COO Andy Olson and vice president of product development Bryce Daines will immediately relocate to St. Louis. PierianDx will maintain a development team in Provo.

“PierianDx is a leader in enabling precision medicine and I am confident that this partnership will significantly accelerate our shared vision of bringing genomics and personalized medicine into everyday healthcare,” said Robison.

Representatives from Healthbox, an investor in Tute and an innovation partner of Intermountain Healthcare, praised the acquisition.

“This type of consolidation is exactly what the industry needs to bring to market the most unified workflow solution for genomic testing,” said Healthbox vice president Jeffrey Ries.

Founded in 2012, Tute Genomics has grown to become an industry-leading bioinformatics software platform. The company was co-founded by Kai Wang, a computational biologist and inventor of Tute’s ANNOVAR software, and Dr. Reid Robison, a physician, geneticist and entrepreneur. In December 2015, Tute Genomics acquired the assets of Knome, a pioneer in human-genome interpretation, co-founded by geneticist and Harvard professor George Church.

PierianDx will maintain the Tute Genomics solution until the platforms are fully integrated into CGW 6.0 in the spring of 2017.